EICHORCondition: Geographic Atrophy · Sponsor: NGM Biopharmaceuticals, Inc
This is a multi-center evaluation of NGM621 in a randomized, double-masked, sham-controlled study in participants with Geographic Atrophy secondary to Age-related Macular Degeneration.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Associated Retina Consultants | Phoenix, Arizona, United States | — |
| California Retina Consultants | Bakersfield, California, United States | — |
| Retina Vitreous Associates | Beverly Hills, California, United States | — |
| Retinal Diagnostic Center | Campbell, California, United States | — |
| The Retina Partners | Encino, California, United States | — |
| Retina Consultants of Orange County | Fullerton, California, United States | — |
| Loma Linda University Health | Loma Linda, California, United States | — |
| University of California Los Angeles | Los Angeles, California, United States | — |
| Northern California Retina Vitreous Associates | Mountain View, California, United States | — |
| Retina Institute of California | Palm Desert, California, United States | — |
| California Eye Specialists | Pasadena, California, United States | — |
| Retina Consultants San Diego | Poway, California, United States | — |
+ 53 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04465955